Exploring Frontline and Second-Line Treatment Options for Metastatic RCC

This chapter delves into the various frontline treatment approaches for metastatic RCC, detailing the combinations of tyrosine kinase inhibitors and immunotherapy agents based on risk criteria. It explores options for favorable risk RCC such as Sit-knit Pembrolyzumab and Cabo's Antinib with Nivolamab, as well as alternatives for intermediate or poor risk RCC like Ipillimumab, Nivolamab combo, and ongoing trials like Cosmic 313 and Pedigree.